Coordinated accumulation of cyclin D1 and D3 is observed in 15% of primary breast cancers and in the breast cancer cell line MCF-7 this simultaneous overexpression is due to a defect in their ubiquitin-mediated proteolysis. The F-box protein Skp2 is a component of an SCF ubiquitin ligase complex and can associate with cyclin D1 and the cdk inhibitor p21 (Zhong-Kang et al., 1998) . We extend this observation and show that cyclin D3 can also associate with Skp2 suggesting that cyclins D1, D3 and p21 may share the same SCF complex. In agreement with this hypothesis we report here that in primary breast cancers and in MCF-7 cells where cyclins D1 and D3 are elevated the level of p21 is also elevated. Further, we demonstrate that the turnover of p21 protein is reduced in MCF-7 cells. We show that p21 is active as a cdk inhibitor in this cell line but that the presence of elevated levels of cyclin D3 titrates p21 away from cyclin D1-cdk4/6 complexes and cdk2 complexes resulting in increased kinase activities. Our results suggest that a defect in the SCF complex may occur in 15 ± 20% of breast cancers and that the resulting coordinated elevation of cyclins D1 and D3 overcomes the inhibition of cell cycle progression by p21. We propose that in the context of cyclins D1 and D3 overexpression, p21 may promote cell cycle progression.
Introduction
Cyclin dependent kinases (cdk) are key cell cycle regulators. Their activities are regulated at several levels including by phosphorylation, binding to their regulatory subunits the cyclins and binding to small inhibitory proteins called the cyclin-dependent kinase inhibitors (CKI) (Morgan, 1995) . Among the cyclin subunits, D-type cyclins associate with cdk4 and 6 to phosphorylate the retinoblastoma (Rb) protein. Hyperphosphorylation of Rb promotes the release of the E2F family of transcription factors that then promote entry into S phase through activation of key target genes (Helin, 1998) . D-type cyclins are rate limiting for the progression from G1 into S phase of the cell cycle (Ando et al., 1993; Musgrove et al., 1994) . Further, expression of cyclin D1 in mouse mammary glands leads to carcinoma, indicating that cyclin D1 acts as an oncogene (Wang et al., 1994) . In human breast cancer, abnormal accumulation of cyclin D1 is observed in up to 35% of cases (Gillett et al., 1994) .
The kinase activity associated with D-type cyclins is limited by rapid degradation of the cyclin subunit through an ubiquitin-dependent proteolytic pathway (Diehl et al., 1997) and by binding to CKIs. The CIP/KIP family of mammalian CKI consists of three members, p21 CIP1/WAF1/SDI1 , p27 KIP1 and p57 KIP2 that regulate cyclin-cdk complex activity in response to various intracellular and extracellular signals (for a review, Sherr and Roberts, 1995) . For example, p21 transcription is induced by the tumour suppressor protein p53 in response to DNA damage in G1 to elicit cell cycle arrest (for a review, Sherr and Roberts, 1995) . More recently p21 has been shown to also be regulated by an ubiquitin-dependent proteolytic pathway (Maki and Howley, 1997) . Interestingly, cyclins D1 and p21 have been shown to be able to associate with the same ubiquitination machinery referred to as the SCF complex (ZhongKang et al., 1998) .
The assembly of ubiquitin molecules onto speci®c proteins to form multiubiquitinated chain results in recognition and subsequent degradation by the 26S proteosome. Linkage of ubiquitin to a protein requires the activity of the ubiquitin activating enzyme or E1, an ubiquitin conjugating enzyme or E2 and an ubiquitin ligase or E3. The SCF complex is composed of three proteins Skp1, a Cullin and an F-box protein (for a review, Krek, 1998) and provides the E3 ligase activity in the ubiquitination of several proteins. Yeast and mammalian cells encode several dierent F-box proteins. In yeast at least three SCF complexes exist SCF Grr1 , SCF Cdc4 and SCF Met30 where the F-box protein encoded by Grr1, Cdc4 or Met30 respectively provides substrate speci®city to the ligase complex (Skowyra et al., 1997; Patton et al., 1998) .
We have previously identi®ed a subclass of breast cancers, which are potentially defective in the proteolysis of D-type cyclins (Russell et al., 1999) . Considering that p21 and D-type cyclins may be degraded by the same pathway (Zhong-Kang et al., 1998), we investigated whether the level of p21 protein is altered in this subset of breast cancers. We found a strong correlation between cyclins D1, D3 and p21 staining in these cancers and propose a model to explain the successful collaboration of these three proteins in cellular proliferation.
Results

Skp2 associates with cyclin D3
We have previously shown that human cyclins D1 and D3 can both associate with a SCF complex containing the cullin Cul-1 (Russell et al., 1999) . Recently, cyclin D1 has been shown to associate not only with Cul-1, con®rming our previous observation, but also with the F-box protein Skp2 (Zhong-Kang et al., 1998) . However, whether cyclin D3 can also associates with the same F-box protein was not determined. To investigate this possibility, U2OS cells were transfected with cyclin D3 and Skp2 and their ability to interact tested by coimmunoprecipitation. As shown in Figure 1 cyclin D3 can associate with Skp2 and this association is enhanced in presence of the 26S proteosome inhibitor LLnL. As Skp2 has been shown to aect p21 level (Zhong-Kang et al., 1998) , our result is consistent with the hypothesis that cyclin D1, cyclin D3 and p21 share a common ubiquitination pathway.
p21 is elevated in cyclin D1 +
D3
+ breast cancers
Cyclins D1 and D3 are coordinately elevated in *15% of breast cancers and we have proposed that this simultaneous accumulation re¯ect a defect in common elements of their proteolysis (Russell et al., 1999) . We reasoned that if D-type cyclins proteolysis is defective in these patients and p21 is degraded by the same proteolytic pathway, p21 should also be elevated. We tested this hypothesis using immunohistochemistry on paran-embedded sections. In this study we found that 20% (14/70) of cancers were positive for cyclins D1 and D3 indicating that this subset of cancers may be more important then we originally estimated. The population of cyclin D1, cyclin D3 doubly positive cancers was then stained for p21. We found that 93% (13/14) D1 + D3 + cancers were also positive for p21 (Table 1 and Figure 2 ). However, in a population of cancers which are D1
, only 53% (30/56) were positive for p21 (Table 1 ). The dierence in p21 staining between the two populations was highly signi®cant (P50.009). This result further provides support for the hypothesis that D1 + D3 + p21 + cancers are defective in the machinery responsible for the degradation of these proteins rather than in other proteins aecting cyclins D1 and D3 degradation speci®cally such as GSK-3b (Diehl et al., 1998) . Further, as *60% of breast cancers have been shown to overexpress p21 but only *30% of these cancers overexpress p53, other p53 independent mechanism leading to p21 overexpression must exist (Rey et al., 1998) . Our results indicate that stabilization of p21 protein may represent such a mechanism. In agreement with our observation, overexpression of p21 has previously been associated with cyclin D1 overexpression (Rey et al., 1998) .
p21 turnover is decreased in MCF-7 cells
To directly address whether a p21 proteolytic defect is observed in breast cancer, the turnover of p21 was determined in the breast cell line MCF-7. We previously showed that the half-life of cyclins D1 and D3 was increased in this cell line (Russell et al., 1999) . In agreement with the data obtained in primary breast cancers, the level of p21 is coordinately elevated with cyclins D1 and D3 in this cell line (Figure 3a) . The half-life of p21 was assessed by cycloheximide chase and found to be increased to more than 60 min in MCF-7 compared to 10 min in U2OS cells (Figure 3b) . Similar results were obtained by 35 S-methionine pulsechase (data not shown) This result suggests that the simultaneous accumulation of cyclins D1, D3 and p21 in MCF-7 cells is due to a common defect in their proteolysis.
p21 partially inhibits cyclins D1-and D3-cdk complexes in MCF-7 cells
The elevated levels of p21 in D1 + D3
+ cancers and in MCF-7 raises the question as to how these cells overcome the inhibitory activity of p21. As p21 has been shown to act as an assembly factor when present in low concentration (LaBaer et al., 1997) , one possibility is that in the presence of elevated cyclins D1 and D3, the relative concentration of p21 is reduced and allows p21 function to be modulated from an inhibitor to an assembly factor. To test this hypothesis, p21 was immunodepleted from MCF-7 cells (Figure 4a ) and the kinase activity associated with cyclins D1 or D3 determined. The kinase activity, analysed by measuring phosphorylation of Rb, was found to be elevated following p21 depletion. This indicates that p21 acts to some extent as an inhibitor in MCF-7 cells (Figure 4b) . However, as immunodepletion failed to remove all of p21 from MCF-7 cell extracts, this observation does not rule out the possibility that at lower concentration p21 acts as an assembly factor. The level of cyclins D1 and D3 was not aected by p21 immunodepletion (Figure 4b ) indicating that p21 immunoprecipitation did not selectively remove D-type cyclins associated with p21.
Cyclin D3 titrates p21 away from cyclin D1-cd4/6 and cdk2 complexes Previous reports have indicated that either raising p21 levels (Sheikh et al., 1995) or lowering cyclin D1 abundance (Lukas et al., 1996) in MCF-7 cells is sucient to induce cell cycle arrest. These results suggest that the level of p21 present in MCF-7 cells is not sucient to completely inhibit cyclin D1 associated kinase activity. We reasoned that the coordinated presence of elevated level of cyclin D3 in these cells might contribute to this eect by titrating excess p21 away from cyclin D1. This possibility was tested by transfecting U2OS cells with either p21 and cyclin D1 alone or in combination with cyclin D3 and determining the amount of p21 associated with cyclin D1 in both cases. As shown in Figure 5a , despite identical amounts of cyclin D1 (Figure 5a ), the amount of p21 associated with cyclin D1 was reduced when cyclin D3 was also present. To con®rm this result we transfected MCF-7 cells with cyclin D3 to further increase the level of cyclin D3 and looked at the amount of p21 associated with cyclin D1. In agreement with the result obtained in U2OS cells, the amount of p21 associated with cyclin D1 was drastically reduced in the presence of increased amount of cyclin D3 (Figure 5b ) while the levels of cyclin D1 were similar. The reduction in p21 associated with cyclin D1 in the presence of cyclin D3 correlated with an increase in cyclin D1 associated kinase activity (Figure 5c,d) .
Further, the amount of p21 associated with cyclin D3 increased in these cells (Figure 5e ) indicating a redistribution of p21 from cyclins D1 to D3 complexes.
These results indicate that the presence of cyclin D3 titrates p21 away from cyclin D1 in MCF-7 cells.
As p21 is a potent inhibitor of cyclins E and A-cdk2 complexes, we next tested whether the overexpression of cyclin D3 in MCF-7 cells also aects cdk2 associated activity. To address this question, MCF-7 cells were transfected with cyclins D3 and cdk2 immunoprecipitated. As shown in Figure 6 , an elevated level of cyclin D3 resulted in a reduced association between p21 and cdk2 (Figure 6a ). Further, this lower level of p21 correlated with an increase in cdk2 kinase activity (Figure 6b ). These results demonstrate that cyclin D3 titrates p21 away not only from cyclin D1 complexes but also from cdk2 associated complexes.
Discussion
Our results support the hypothesis that cyclins D1, D3 and p21 share the same ubiquitin ligase complex and further reinforces the notion that this process is defective in 15 ± 20% of breast cancers. The precise nature of this defect is being investigated. Further, our results propose a model to explain the growth of MCF-7 cells in the presence of elevated p21. This model reconciles previous observations on the eect of reducing cyclin D1 and increasing p21 on MCF-7 proliferation and proposes that the presence of cyclin D3 titrates p21 away from cyclins D1 and cdk2 complexes. In this context, although p21 is active as an inhibitor against cyclin D1, the presence of cyclin D3 allows sucient cyclin D1 associated cdk activity to promote progression. Cyclin D3 overexpression has also been shown to accelerate G1-S progression (Bartkova et al., 1998) , although the ability of cyclin D3 to act as an oncogene has not been directly demonstrated. Therefore the distinct possibility exists that the presence of cyclin D1 in MCF-7 cells titrates p21 away from cyclin D3, allowing cyclin D3 associated kinase activity to also contribute to cell cycle progression. However we were unable to obtain direct demonstration of this eect. Nevertheless, our results clearly demonstrate that cyclin D3 aects cyclin D1 association with p21 and alters its associated kinase activity. The residual p21 associated with cyclin D1 may in fact promote the activity of this cdk complex as p21 acts as an assembly factor when present at a lower concentration (LaBaer et al., 1997) . This notion has recently been con®rmed by the ®nding that mouse ®broblast defective in both p21 and p27 fail to assemble cyclin D-cdk4 complexes (Cheng et al., 1999) . The positive action of p21 on D-type cyclincdk complexes provides an explanation as to why these proteins may share a common proteolytic machinery. In cycling cells an equal balance between D-type cyclins and p21 may be required for their activities. However, when this balance is modulated, for instance by induction of higher p21 levels by p53 transcriptional activity, the eect of p21 may only then be converted into an inhibitory action toward D-type cyclin-cdk complexes.
Clearly, in MCF-7 cells where degradation of D-type cyclins and p21 is simultaneously aected, the inhibitory action of p21 is insucient and in this context p21 may promote the activity of cyclins D1 and D3-cdk complexes. Our ®nding that 15 ± 20% of breast cancers are positive for these three proteins support this notion and raises a new interpretation of p21 positive immunostaining in cancers.
In breast cancer, cyclin D3 overexpression is restricted compared to cyclins D1 (35%) and p21 (60%). Analysis of cyclin D3 overexpression in multiple cancers types has revealed that such an event is speci®c to breast carcinomas . As cyclin D3 positive breast cancers are almost entirely positive for cyclins D1 and p21, cyclin D3 staining may be a marker for defect in proteolysis and such defect may be particularly frequent in breast cancer.
We have shown that overexpression of cyclin D3 leads to the activation of cdk2 associated kinase activity. This results indicates that in addition to enhance the activity associated with cyclin D1, the overexpression of cyclin D3 enhances cyclin E and cyclin A associated kinase activities. Therefore, cyclin D3 acts as a`p21 sponge' and allows a massive activation of multiple cyclin dependent kinases.
Materials and methods
Transfection, protein extraction and immunoprecipitation
U2OS and MCF-7 cells were transfected by lipofection using the FuGENE TM 6 system as described by the manufacturer (Boehringer Mannheim) with 2 ug of pCDNA3-cyclinD3, pCDNA3-cyclinD1, pCDNA3-p21 or pCDNA3-Skp2. Protein extraction and immunoprecipitation were performed as described elsewhere (Russell et al., 1999) . For inhibition of the 26S proteosome, cells were treated with the peptide aldehyde leucinyl-leucinyl-norleucinyl (LLnL) solubilized in DMSO at a ®nal concentration of 100 mM for 4 h. Following immunoprecipitation, proteins were resolved on 12% polyacrylamide gels, transferred onto nitrocellulose membranes, subjected to standard Western blotting analysis and visualised using ECL (Amersham Life Science). For detection Cdk2 associated H1 kinase activity was determined of Skp2, the rabbit polyclonal antibody N19 (Santa Cruz) was used at a dilution of 1 : 100. For detection of cyclins D1, D3 and p21 rabbit polyclonal antibodies M-20, C-16 and H164 (Santa Cruz) respectively at a dilution of 1 : 100. For detection of actin, the monoclonal antibody N350 (Amersham Life Science) was used at a dilution of 1 : 2000.
Cycloheximide chase of p21 in U2OS and MCF-7 cells was performed as described elsewhere (Maki and Howley, 1997) .
Immunostaining
Immunostaining of paran sections was performed as described elsewhere (Russell et al., 1999a) , using a rabbit polyclonal antibody against human p21 H164 (Santa Cruz) at a concentration of 1 : 500.
Comparisons of the two percentages were performed using the Fisher Exact test. A two-sided test was carried out and results with a P-value less than 0.05 were considered signi®cant. The StatXact-4 statistical package was used.
Immunodepletion and Rb kinase activity
For immunodepletion MCF-7 cells were lysed in 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP40, 0.1 mM sodium¯uoride, 0.1 mM sodium orthovanadate and the lysates clari®ed by centrifugation at 13 000 r.p.m. for 20 min at 48C. The supernatant was divided in two and one half was subjected to immunodepletion using the rabbit polyclonal antibody #15431E against anti-human p21 (Becton Dickinson) while the other half was treated with either with protein A beads only or with an unrelated polyclonal antibody. Following p21 immunoprecipitation supernatants were transferred to new tubes for immunoprecipitation of cyclins D1 and D3.
Rb kinase activity was performed as described elsewhere (Matsushime et al., 1994) .
